

# Press Release



## Newsweek International Features ASKA Pharmaceutical

---

**TOKYO, March 21, 2024** - ASKA Pharmaceutical Holdings Co., Ltd. (TSE:4886) is pleased to announce that Sohta Yamaguchi, President, Representative Director of its subsidiary, ASKA Pharmaceutical Co., Ltd. (hereinafter "ASKA"), was interviewed by the news agency, the Worldfolio PTE. LTD. and the article introducing ASKA was published in the US weekly magazine "Newsweek International." Please see the attached for the article content.

Reference: [Newsweek International Features ASKA Pharmaceutical \(aska-pharma-hd.co.jp\)](https://www.newsweek.com/aska-pharma-hd-co-jp)

\* announced on September 14, 2023

Newsweek is an American weekly magazine with a global readership of approximately 46 million people, and provides information on all areas of global culture, politics, economics, and social conditions. For the special feature "The Japanese Firms Accelerating Medical Innovation," Newsweek introduced ASKA as one of the firms in this issue.

The full interview is posted on the news website "The WORLDFOLIO."

<https://www.theworldfolio.com/interviews/aska-we-create-new-value-as-leading-womens-healthcare-company/5872/>

\* The Worldfolio PTE. LTD. has granted permission to post the article here.

### **The Worldfolio PTE. LTD. :**

The Worldfolio is a media agency and a news website that has been bringing high-quality content to readers around the globe for over 20 years. The Worldfolio PTE LTD is now based in Singapore and provides breaking news, in-depth analyses, and investigative stories about a wide range of topics and sectors, including manufacturing, real estate, construction, healthcare, digital transformation and more.

---

### **Media Contacts**

ASKA Pharmaceutical Holdings Co., Ltd.

Corporate Planning Department

Tel: +81-3-5484-8366

Email: [kouhou@aska-pharma.co.jp](mailto:kouhou@aska-pharma.co.jp)

# The World's Best Hospitals

# INTERNATIONAL Newsweek®

# RX: AI

HOSPITAL  
BOSSSES ARE  
BETTING ON  
**BIG TECH**

■ ■ ■



1 5 . 0 3 . 2 0 2 4

ISSN 2052-1081



ALBANIA €6.25	DENMARK DKR57	HONG KONG HK\$80	LITHUANIA €8.99	OMAN OR 3.250	SINGAPORE S\$19.95	UK £5.99
AUSTRALIA \$11.00	EGYPT E£ 65.00	HUNGARY HUF 5.990	LUXEMBOURG €790	POLAND PLN29.99	SLOVAKIA €6.50	US \$10.99
AUSTRIA €10.00	FINLAND €760	IRELAND €700	MALTA €700	PORTUGAL €700	SOUTH AFRICA R55.00	ZIMBABWE ZWD4.00
BAHRAIN BD4.25	FRANCE €7.50	ISRAEL NIS35	MONTENEGRO €8.30	QATAR QR65	SPAIN €700	
BELGIUM €700	GERMANY €7.50	ITALY €700	MOROCCO MDH70	MALAYSIA RM27.90	SWEDEN SKR119	
CHINA RMB80	GIBRALTAR €6.05	KUWAIT KD3.00	NEW ZEALAND \$14.00	ROMANIA LEI 42.00	SWITZERLAND	
CYPRUS €700	GREECE €7.50	LATVIA €6.50	NIGERIA \$3.40C	SAUDI ARABIA SR35.00	CHF10.60	
CZECH REP CZK180	HOLLAND €7.00	LEBANON LL10,000	NORWAY NKR119	S LEONE SLL30,000	UAE AED42	

# ASKA Pharmaceutical: Revolutionizing Women's Healthcare

In its drive to become a women's healthcare pioneer, ASKA Pharmaceutical is committed to innovation and global expansion.



Head office in Tokyo

ASKA Pharmaceutical is today the leading force in Japan's obstetrics and gynecology sector, showcasing a relentless pursuit of excellence in women's healthcare that demonstrates its commitment beyond mere sales figures. "We aim to become a total healthcare company and a global entity, aligning with our corporate philosophy," says Sohta Yamaguchi, the company's president.

ASKA's strategic shift to a holdings model enables the company to offer comprehensive health



"We aim to become a total healthcare company and a global entity."

**Sohta Yamaguchi,**  
President,  
ASKA Pharmaceutical


services, from prevention to post-treatment, meeting the evolving needs of a proactive populace. With innovative products like RELUMINA (relugolix) for uterine fibroids and endometriosis, and essential products in the treatment of thyroid disease, ASKA Pharmaceutical stands out by providing effective solutions.

"We offer drugs that provide treatment options for women's health challenges at every stage of life," Mr. Yamaguchi explains. "We aim to not only provide

drugs and treatments but also medical equipment and related services, offering comprehensive health services for females."

And in a world where self-medication is on the rise, ASKA Pharmaceutical sees opportunities, not obstacles. "Over-the-counter options are gaining popularity, and this has led to the growing health consciousness of the Japanese people and the revitalization of the healthcare market," he adds.

Looking forward, Mr. Yamaguchi en-



Three core areas with a focus on pharmaceuticals



Drugs for the treatment of thyroid disease when launched in 1922

visions a future where ASKA expands globally, enriching lives beyond Japan's borders. "By our 105th anniversary in 2025, I hope to report our successful achievements," he shares, hinting at forthcoming advancements in global expansion and new business ventures.

In a nutshell, ASKA Pharmaceutical isn't just about treating ailments; it's about empowering women, fostering health awareness, and pioneering innovations that transcend borders. With Mr. Yamaguchi at the helm, the company's journey towards global leadership in women's health seems not just promising but inevitable.

 **ASKA Pharmaceutical Co., Ltd.**  
[www.aska-pharma.co.jp](http://www.aska-pharma.co.jp)